NeuroMetrix Reports Agreement with GSK Healthcare on 2019 Quell Joint Development Program and Modification to Strategic Collaboration

11:47 EST 12 Dec 2018 | Investing News Network

NeuroMetrix (Nasdaq:NURO) today reported momentum in its strategic collaboration with GSK Consumer Healthcare. As quoted in the press release: Under terms of the collaboration entered into in the first quarter of 2018, the parties committed to co-fund future development of Quell® technology beginning in 2019, subject to agreement on an annual program of product initiatives. The … Continued

More From BioPortfolio on "NeuroMetrix Reports Agreement with GSK Healthcare on 2019 Quell Joint Development Program and Modification to Strategic Collaboration"